Integral Health Asset Management, LLC Altimmune, Inc. Transaction History

Integral Health Asset Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$8.43 - $16.81 $1.35 Million - $2.69 Million	-160,000 Closed	0 $0
Q2 2021 Aug 30, 2021	SELL	$9.85 - $16.46 $1.58 Million - $2.63 Million	-160,000 Reduced 50.0%	160,000 $1.58 Million
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $3.15 Million - $5.27 Million	320,000 New	320,000 $3.15 Million

190

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $326M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.